Ark Invest highlights genomics potential, benefiting CRISPR Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Jan 26
Source: Benzinga
CRISPR Therapeutics AG's stock rose by 9.09% as it crossed above the 20-day SMA, reflecting positive market sentiment.
The recent Ark Invest report emphasized the investment opportunities in genomics, with a specific mention of CRISPR Therapeutics as a beneficiary of this trend. This aligns with the growing interest in molecular diagnostics and innovative technologies, which could drive further growth for the company.
As the market continues to show strength, CRISPR Therapeutics is well-positioned to capitalize on these emerging trends in the genomics sector.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
11 Buy
7 Hold
0 Sell
Moderate Buy
Current: 54.260
Low
40.00
Averages
68.88
High
105.00
Current: 54.260
Low
40.00
Averages
68.88
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
